Fundraising FoxBlue Owl Capital — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Co-investorsAltium CapitalHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)BAM ElevateBiotechnology Value Fund+1 more
Interos.ai provides supply chain risk management software that monitors financial, compliance, environmental, cybersecurity, and geopolitical risks across supplier networks using its i-Score metric.
Data & InfrastructureEnterprise SoftwareLogistics & Supply ChainArlington, US
Jennifer Bisceglie(Founder)inTed Krantz(Executive Officer, Director)Theodore Krantz Jr.in
BoardFrank Verdecanna(Director)Phil Venables(Director)inNick Beim(Director)in
Co-investorsAllegisCyber CapitalAlleyCorpBallistic VenturesDeclaration PartnersForgePoint CapitalHakluyt Capital+6 more
Perk provides AI and automation that handles routine administrative tasks — travel, expenses, invoices, and payments — for employees, while giving companies visibility and configurable controls for policy, governance, and risk.
AI & Machine LearningEnterprise SoftwareFintechSaaSTravel & HospitalityBoston, US
Avi Meir(Founder)inJavier Suarez(Founder)inADAM SALOMON(Executive Officer)JEFF COLLINS(Executive Officer)TED HASTINGS(Executive Officer)SUROJIT NIYOGI(Executive Officer, Director)
Co-investorsAmplo VenturesAtomicoClaltechD&FG ElementsFELIX CAPITALGeneral Catalyst+17 more
.png)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.